- Conditions
- HIV Infections
- Interventions
- Zidovudine, Zalcitabine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 40
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2497–2520
of 9,158
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Risdiplam
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 2 Months and older
- U.S. locations
- 29
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
- Conditions
- Haemophilia A
- Interventions
- Denecimig
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 18
- States / cities
- Iowa City, Iowa • Metairie, Louisiana • Minneapolis, Minnesota + 15 more
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Ninerafaxstat 200mg MR, Placebo
- Drug
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 26
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
- Interventions
- VG161, Nivolumab Injection [Opdivo]
- Drug
- Lead sponsor
- Virogin Biotech Canada Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
- Drug
- Lead sponsor
- Clarity Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Stanford, California • River Ridge, Louisiana • Grand Rapids, Michigan + 4 more
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- filgrastim, amifostine trihydrate, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Indianapolis, Indiana • Burnsville, Minnesota + 12 more
- Conditions
- Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
- Interventions
- Envafolimab, Ipilimumab
- Biological · Drug
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more
- Conditions
- Neurofibromatosis Type 1, Precancerous Condition
- Interventions
- pirfenidone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more
- Conditions
- Amyloidosis
- Interventions
- Belantamab mafodotin, Cyclophosphamide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 5 more
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 480
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
- Conditions
- Colorectal Cancer
- Interventions
- BBI608, Panitumumab, Capecitabine, Cetuximab
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Jacksonville, Florida + 10 more
- Conditions
- Stress Urinary Incontinence
- Interventions
- Cadence Increase, Cadence Maintenance
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Scoliosis, Adolescent Idiopathic Scoliosis
- Interventions
- Maximum Number of Screws, Minimum Number of Screws
- Procedure
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Washington D.C., District of Columbia + 10 more
- Conditions
- Charcot-Marie-Tooth Disease
- Interventions
- FLX-787-ODT (orally disintegrating tablet), Placebo ODT
- Drug
- Lead sponsor
- Flex Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • New Britain, Connecticut + 16 more
- Conditions
- Breast Cancer, Hot Flashes
- Interventions
- gabapentin, antidepressant
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 162
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Augusta, Georgia + 101 more
- Conditions
- Urothelial Carcinoma
- Interventions
- MV-NIS
- Biological
- Lead sponsor
- Vyriad, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- Miami, Florida • New Orleans, Louisiana • Rochester, Minnesota
- Conditions
- Pareses, Lower Extremity
- Interventions
- C-Brace
- Device
- Lead sponsor
- Otto Bock Healthcare Products GmbH
- Industry
- Eligibility
- Not listed
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 70
- States / cities
- Harrison, Arkansas • Rogers, Arkansas • San Diego, California + 63 more
- Conditions
- IgA Nephropathy
- Interventions
- OMS721, Vehicle (D5W or saline)
- Biological · Other
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 34
- States / cities
- Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more
- Conditions
- Lung Cancer, Squamous Lung Dysplasia, Tobacco Use Disorder
- Interventions
- deuterated phenanthrene tetraol, pharmacological study, laboratory biomarker analysis
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Buffalo, New York
- Conditions
- Chronic Thromboembolic Pulmonary Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 32
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more
- Conditions
- Sarcoma
- Interventions
- sargramostim, cisplatin, dacarbazine, doxorubicin hydrochloride, mitomycin C
- Biological · Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
- Conditions
- Amyloid Light-chain Amyloidosis
- Interventions
- BCMA bispecific
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Cleveland, Ohio
- Conditions
- Hemophilia A
- Interventions
- Efanesoctocog Alfa BIVV001
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 28
- States / cities
- Gilbert, Arizona • Loma Linda, California • Los Angeles, California + 23 more